Ophthalmic devices, such as contact lenses, may incorporate myopia controloptics in combination with therapeutic agents also known to control myopia tocreatea drug delivery mechanism to inhibit or arrest the progression of myopia inindividuals. Any number of contact lenses incorporating myopia control opticsmaybe combined with a therapeutic agent such as atropine, atropine sulphatemonohydrate, and/or pirenzepine